A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Status: Recruiting
Location: See all (130) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 90
Healthy Volunteers: f
View:

∙ \- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology:

∙ i) Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), Aβ42/40 ratio in CSF, pTau181/Aβ42 ratio in CSF or pTau217/Aβ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay.

∙ ii) If no historical evidence available:

∙ A. A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval.

∙ B. If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:

• Amyloid PET.

• Aβ42/40 ratio or pTau181/Aβ42 ratio in CSF using an HA-authorized diagnostic assay.

‣ Mini-Mental State Examination (MMSE) score of 5 to 22, inclusive, at Screening (Visit 1).

⁃ Have one identified caregiver who should have sufficient contact (approximately 10 hours a week or more) and is willing to:

‣ i) Attend all visits and report on participant's status.

∙ ii) Oversee participant compliance with medication and study procedures.

∙ iii) Participate in the study assessments and provide informed consent to participate in the study.

• History of agitation that meets the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders with onset at least two weeks prior to Screening (Visit 1).

• AD participants are required to have NPI/NPI-NH Agitation/Aggression score ≥ 4 at Screening (Visit 1) and Baseline (Visit 2).

• CGI-S ≥ 4, as related to agitation, at Screening (Visit 1) and Baseline (Visit 2).

• At least 1 of the following 3 criteria must be established from the CMAI-IPA at Screening (Visit 1) and Baseline (Visit 2; CMAI-IPA Physical/Verbal Aggression Positivity):

• i) 1 or more aggressive behaviors occurring at least several times per week.

∙ ii) 2 or more aggressive behaviors occurring at least once or twice per week.

∙ iii) 3 or more aggressive behaviors occurring less than once per week.

Locations
United States
Arizona
Chandler Clinical Trials, LLC
RECRUITING
Chandler
Local Institution - 2631
NOT_YET_RECRUITING
Chandler
California
Local Institution - 2607
NOT_YET_RECRUITING
Long Beach
Local Institution - 2625
NOT_YET_RECRUITING
Long Beach
Local Institution - 2642
NOT_YET_RECRUITING
Long Beach
Local Institution - 2627
NOT_YET_RECRUITING
Napa
Local Institution - 2613
NOT_YET_RECRUITING
Pasadena
Local Institution - 2614
NOT_YET_RECRUITING
San Diego
Alliance Clinical -West Hills
RECRUITING
West Hills
Colorado
Local Institution - 2601
WITHDRAWN
Basalt
Local Institution - 2635
NOT_YET_RECRUITING
Colorado Springs
Connecticut
Local Institution - 2632
NOT_YET_RECRUITING
Norwalk
Florida
Envision Trials LLC
RECRUITING
Bonita Springs
Key Clinical Research
RECRUITING
Bradenton
Local Institution - 2636
NOT_YET_RECRUITING
Doral
Local Institution - 2626
NOT_YET_RECRUITING
Hialeah
Local Institution - 2606
NOT_YET_RECRUITING
Homestead
Local Institution - 2633
NOT_YET_RECRUITING
Miami
Local Institution - 2637
NOT_YET_RECRUITING
Miami
Local Institution - 2634
NOT_YET_RECRUITING
Orlando
IPTB Clinical Research
RECRUITING
Tampa
Georgia
Agile Clinical Research Trials, LLC
RECRUITING
Atlanta
Massachusetts
Vitalix Clinical
RECRUITING
Worcester
Michigan
Michigan Clinical Research Institute PC
RECRUITING
Ann Arbor
Minnesota
Local Institution - 2630
NOT_YET_RECRUITING
Saint Paul
Missouri
Sharlin Health Neuroscience Research Center
RECRUITING
Ozark
Mississippi
Hattiesburg Clinic
RECRUITING
Hattiesburg
North Carolina
West Clinical Research
RECRUITING
Morehead City
Nevada
Las Vegas Clinical Trials
RECRUITING
Las Vegas
New York
Richmond Behavioral Associates
RECRUITING
Staten Island
Ohio
Velocity Clinical Research - Blue Ash
RECRUITING
Blue Ash
Texas
Epic Medical Research, LLC - Carrolton
RECRUITING
Carrollton
Local Institution - 2605
NOT_YET_RECRUITING
Cypress
Epic Medical Research, LLC - Mesquite
RECRUITING
Mesquite
Local Institution - 2623
NOT_YET_RECRUITING
San Antonio
Utah
Pantheon Clinical Research, LLC
RECRUITING
Bountiful
Washington
Local Institution - 2638
NOT_YET_RECRUITING
Kirkland
Wisconsin
Local Institution - 2610
NOT_YET_RECRUITING
Milwaukee
Other Locations
Argentina
Local Institution - 2004
NOT_YET_RECRUITING
Buenos Aires
Local Institution - 2006
NOT_YET_RECRUITING
Buenos Aires
Local Institution - 2005
NOT_YET_RECRUITING
Ciudad Autonoma De Buenos Aires
Local Institution - 2000
NOT_YET_RECRUITING
Córdoba
Local Institution - 2002
NOT_YET_RECRUITING
Córdoba
Local Institution - 2003
NOT_YET_RECRUITING
Córdoba
Local Institution - 2001
NOT_YET_RECRUITING
Mendoza
Chile
Local Institution - 2053
NOT_YET_RECRUITING
Antofagasta
Local Institution - 2050
NOT_YET_RECRUITING
Santiago
Local Institution - 2051
NOT_YET_RECRUITING
Santiago
Local Institution - 2052
NOT_YET_RECRUITING
Santiago
Local Institution - 2055
NOT_YET_RECRUITING
Viña Del Mar
Local Institution - 2054
NOT_YET_RECRUITING
Vitacura
France
Local Institution - 2153
NOT_YET_RECRUITING
Lille
Local Institution - 2156
NOT_YET_RECRUITING
Limoges
Local Institution - 2157
NOT_YET_RECRUITING
Montpellier
Local Institution - 2152
NOT_YET_RECRUITING
Paris
Local Institution - 2155
NOT_YET_RECRUITING
Strasbourg
Centre Hospitalier Universitaire Toulouse - Cité de la Santé
RECRUITING
Toulouse
Local Institution - 2151
NOT_YET_RECRUITING
Villeurbanne
Germany
Local Institution - 2201
NOT_YET_RECRUITING
Düsseldorf
Local Institution - 2203
NOT_YET_RECRUITING
Erbach Im Odenwald
Local Institution - 2205
NOT_YET_RECRUITING
Halle
Local Institution - 2206
NOT_YET_RECRUITING
Westerstede
Hungary
Local Institution - 2251
WITHDRAWN
Budapest
Local Institution - 2253
NOT_YET_RECRUITING
Budapest
Local Institution - 2255
NOT_YET_RECRUITING
Budapest
Local Institution - 2256
NOT_YET_RECRUITING
Budapest
Local Institution - 2252
NOT_YET_RECRUITING
Debrecen
Local Institution - 2254
NOT_YET_RECRUITING
Gyöngyös
Local Institution - 2250
NOT_YET_RECRUITING
Győr
Local Institution - 2257
NOT_YET_RECRUITING
Kalocsa
Israel
Local Institution - 2301
NOT_YET_RECRUITING
Jerusalem
Sanz MC, Laniado Hospital
RECRUITING
Netanya
Local Institution - 2302
NOT_YET_RECRUITING
Petch Tikva
Local Institution - 2300
NOT_YET_RECRUITING
Ramat Gan
Local Institution - 2305
NOT_YET_RECRUITING
Ramat Gan
Local Institution - 2304
NOT_YET_RECRUITING
Rishon Le'tzion
Italy
Local Institution - 2356
NOT_YET_RECRUITING
Brescia
Local Institution - 2355
WITHDRAWN
Isernia
Local Institution - 2353
NOT_YET_RECRUITING
Milan
Local Institution - 2351
NOT_YET_RECRUITING
Napoli
Local Institution - 2350
NOT_YET_RECRUITING
Pisa
Local Institution - 2357
NOT_YET_RECRUITING
Roma
Local Institution - 2352
NOT_YET_RECRUITING
Rome
Local Institution - 2354
NOT_YET_RECRUITING
Rome
Poland
Local Institution - 2454
NOT_YET_RECRUITING
Bydgoszcz
Local Institution - 2456
NOT_YET_RECRUITING
Chorzów
Local Institution - 2455
NOT_YET_RECRUITING
Katowice
Local Institution - 2451
NOT_YET_RECRUITING
Lublin
Local Institution - 2452
WITHDRAWN
Lublin
Local Institution - 2450
NOT_YET_RECRUITING
Poznan
Local Institution - 2453
NOT_YET_RECRUITING
Sochaczew
Puerto Rico
Local Institution - 2639
NOT_YET_RECRUITING
San Juan
Local Institution - 2640
NOT_YET_RECRUITING
San Juan
Local Institution - 2641
NOT_YET_RECRUITING
San Juan
Republic of Korea
Kyungpook National University Chilgok Hospital
RECRUITING
Deagu
Gachon University Gil Medical Center
RECRUITING
Incheon
Inha University Hospital
RECRUITING
Incheon
Asan Medical Center
RECRUITING
Seoul
Gangnam Severance Hospital, Yonsei University Health System
RECRUITING
Seoul
Konkuk University Medical Center
RECRUITING
Seoul
Local Institution - 2406
WITHDRAWN
Seoul
Seoul National University Hospital
RECRUITING
Seoul
SMG-SNU Borame Medical Center
RECRUITING
Seoul
The Catholic University of Korea, Yeouido St.Mary's Hospital
RECRUITING
Seoul
Ukraine
Local Institution - 2554
NOT_YET_RECRUITING
Dnipro
Local Institution - 2556
NOT_YET_RECRUITING
Hlevakha
Local Institution - 2566
NOT_YET_RECRUITING
Hlevakha
Local Institution - 2550
NOT_YET_RECRUITING
Kropyvnytskyi
Local Institution - 2553
NOT_YET_RECRUITING
Kyiv
Local Institution - 2565
NOT_YET_RECRUITING
Kyiv
Local Institution - 2560
NOT_YET_RECRUITING
Lutsk
Local Institution - 2552
NOT_YET_RECRUITING
Lviv
Local Institution - 2558
NOT_YET_RECRUITING
Lviv
Local Institution - 2569
NOT_YET_RECRUITING
Lviv
Local Institution - 2568
NOT_YET_RECRUITING
Odesa
Local Institution - 2567
NOT_YET_RECRUITING
Oleksandrivka
Local Institution - 2557
NOT_YET_RECRUITING
Poltava
Local Institution - 2559
NOT_YET_RECRUITING
Skarzhyntsi
Local Institution - 2555
NOT_YET_RECRUITING
Smila
Local Institution - 2551
NOT_YET_RECRUITING
Vinnytsia
United Kingdom
Local Institution - 2502
NOT_YET_RECRUITING
Cambridge
Surrey and Borders Partnership NHS Foundation Trust
RECRUITING
Chertsey
Local Institution - 2500
NOT_YET_RECRUITING
London
Local Institution - 2501
NOT_YET_RECRUITING
London
NeuroClin Glasgow
RECRUITING
Motherwell
Local Institution - 2505
NOT_YET_RECRUITING
Preston
Cornwall Partnership NHS Foundation Trust
RECRUITING
Redruth
Local Institution - 2504
NOT_YET_RECRUITING
Sheffield
Local Institution - 2509
WITHDRAWN
Stafford
Local Institution - 2503
NOT_YET_RECRUITING
Wolverhampton
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain the NCT# and Site #.
Time Frame
Start Date: 2025-07-16
Estimated Completion Date: 2028-11-13
Participants
Target number of participants: 352
Treatments
Experimental: KarXT + KarX-EC
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb

This content was sourced from clinicaltrials.gov